Abcellera Biologics is trading at $13.23, up 4.17%, with the specific reason for its September 28 intraday rise still unclear.
- No clear company-specific announcement explaining the gain was identified; the latest company release found was dated September 2.
- Broader markets were moving lower amid rising oil prices and interest-rate concerns, a backdrop that does not explain the stock’s opposite-direction move.